Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04873089
Other study ID # RV3278A2018243
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 17, 2018
Est. completion date December 21, 2018

Study information

Verified date April 2021
Source Pierre Fabre Dermo Cosmetique
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to evaluate, at different times, the RV3278A - ET0943 cosmetic product efficacy after 8 weeks of application on the face (twice-daily application). At T1 (Baseline), T2 (4 weeks) and T3 (8 weeks), the following assessments are performed: - The reduction of the pilosebaceous follicular ostium size in vivo (pores) on the forehead - The clinical evaluation (count of non inflammatory and inflammatory acne lesions, IGA score) of the face - The reduction in visible follicles - The standardized numerical photographs of face and ¾ right and left profile in normal, parallel polarized, cross polarized and UV light - The analysis of the skin lipids of the forehead - The qualitative and quantitative analysis of the sebum and comedones constituents (nose wings) This is a comparative, open-labelled study, on subjects with oily and acne prone skins on the face. Each group includes 18 subjects.


Description:

This study is monocentric, comparative versus non-treated group, open-labelled, exploratory, conducted in adults having oily and acne prone skin. The study includes 4 visits for each group, including subjects' selection: - V0: Subjects' selection - V1: Baseline inclusion - V2: 4 weeks, follow-up visit - V3: 8 weeks, study end The maximal study duration is 61 days. The front, temporal areas and nose wings are defined as the study interest areas for superficial samples. The evaluation is at 3 times: T1 baseline, T2 at 4 weeks and T3 at 8 weeks of application of RV3278A formula ET0943 with comparison of each time versus baseline. There are twice-daily applications (morning and evening) of the test product on the face.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date December 21, 2018
Est. primary completion date December 21, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: 1. Criteria related to the population: - Male or Female aged between 18 and 35 years included - Subject with phototype I to IV included - Subject having signed his/her written informed consent for his/her participation in the study - Subject who is currently not participating in another clinical study - Subject affiliated to a social security system or health insurance, or is a beneficiary - For woman of childbearing potential: use of an effective method of contraception and using it during the whole duration of the study 2. Criteria related to diseases and general health: - Subject with oily, blemished skin and dilated pores on the face including open and closed comedones of the retention type (on the forehead, temporal areas and nose wings) and some inflammatory lesions: - Retention aspect: microcomedones and open comedones count on the forehead (> 10) - Inflammatory aspect: lesions = 10 count on the whole face Exclusion Criteria: 1. Criteria related to the population: - For woman of childbearing potential: subject pregnant or breastfeeding or planning to be pregnant during the study - Subject having already known allergy to latex - Subject having already known allergy to the test product or associated product components - Subject having scar(s) or other skin characteristic on the study areas (forehead, temporal areas and nose wings) and which, size is not compatible with the study realization - Subject who, has planned to apply exfoliating, keratolytic and/or self-tanning products on the face within 2 weeks prior to inclusion. - Subject who, has planned to be exposed to the natural or artificial UV during the study - Subject who is not likely to be compliant with study-related requirements - Subject deprived of freedom by administrative or legal decision or under guardianship 2. Criteria related to diseases and general health: - Inflammatory or immunological dermatosis (atopic dermatitis, psoriasis, severe inflammatory acne, cutaneous seborrhoeic dermatitis, vitiligo of the face..) of the face, or other dermatological face illness in progress at the time of inclusion on the sample areas (pigmentation of the sample areas by melasma, solar erythema or artificial post UV...) 3. Criteria related to treatments - Facial treatments : - Any topical anti-acne antibiotics (topical Erythromycin or topical Dalacin) applied during more than 5 consecutive days within 4 weeks before the inclusion - Any topical treatment (dermo corticoids, retinoids, antibiotics, antifungals…) ongoing or applied within 4 weeks before the inclusion - Oral intake of antibiotic, zinc gluconate or hormonal anti-acne treatments, ongoing or taken during more than 5 consecutive days within the month before the inclusion - Oral intake of isotretinoin within 6 months before the inclusion - Anti-inflammatory treatments (steroids or no steroids) according to the investigator's assessment - Hormonal contraception established or modified within 3 months before the inclusion - Application of skin care product containing exfoliating, keratolytic or self-tanning ingredients applied on the face within 15 days before the inclusion - Oral treatment (cardiovascular, endocrinal, rheumatological, urogenital, neuropsychiatric, immunosuppressant) established within 2 months before the inclusion not stabilized - Hygiene, skin care or make-up habits modified within less than one month before the inclusion

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Cosmetic product
It is a comparative study with two parallel groups of subjects: Tested group: twice daily application of the cream RV3278A cosmetic product on the whole face Comparative group: no application of study product or reference product

Locations

Country Name City State
France Skin Research Centre Toulouse

Sponsors (1)

Lead Sponsor Collaborator
Pierre Fabre Dermo Cosmetique

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of the product on lesions count (Lucky method) Inflammatory and lesions quantification on the whole face Change from baseline to 8 weeks later, for each group
Secondary Efficacy of the product on lesions count (Lucky method) Inflammatory and lesions quantification on the whole face Change from baseline to 4 weeks later, for each group
Secondary Forehead acne lesions count (target area) Change from baseline to 4 weeks and 8 weeks later for each group, on the target area
Secondary Investigator Global Assessment (IGA) on 5-point scale Clear = 0, Almost clear = 1, Mild = 2, Moderate = 3, Severe = 4 Change from 4 weeks to 8 weeks later, for each group, on the target area
Secondary Sebum harvest and analysis Quantification of free fatty acid (FFA) / triglyceride (TG) ratio by infrared spectroscopy: Forehead sebum was collected on absorbent paper then the lipid composition was analysed by infrared spectroscopy to determine the free fatty acids to triglycerides ratio At baseline and after one month of tested product treatment
Secondary Comedones lipid harvest and analysis Quantification of free fatty acid / triglyceride ratio by GC/MS: Samples were collected with patch on nose wings. Comedones were collected and lipids extracted according to the Bligh & Dyer (Bligh and Dyer, 1959). The biochemical exploration was performed by the screening of neutral lipids on GC/MS At baseline and after one month of tested product treatment
Secondary Skin lipids Measure by FTIR spectroscopy (in vivo non invasive infrared analysis) Change from baseline to 4 weeks and 8 weeks later, for each group, on the target area
Secondary Pilosebaceous follicular ostium size in vivo Measure by confocal microscope Change from baseline to 4 weeks and 8 weeks later, for each group, on the target area
Secondary Dilated pores on 5-point scale Absent = 0, Very mild = 1, Mild = 2, Moderate = 3, Severe = 4 Change from baseline to 4 weeks and 8 weeks later, for each group, on the target area
Secondary Patient Global Assessment (PGA) on 6-points scale Clear worsening = 0, slight worsening = 1, no change = 2, slight improvement = 3, clear improvement = 4, total improvement = 5 Change from 4 weeks to 8 weeks later, for each group, on the target area
Secondary Self product agreement questionnaire 9-question questionnaire with a majority of scales ranging from 0 to 10 where 0 was the worst satisfaction and 10 the best one At week 8, for tested group
Secondary Visible follicles quantification by in vivo visualisation methods Count by multispectral imaging Change from baseline to 4 weeks and 8 weeks later, for each group, on the target area
See also
  Status Clinical Trial Phase
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Completed NCT05131373 - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris Phase 1
Completed NCT04806594 - Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar. N/A
Recruiting NCT03465150 - Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital
Completed NCT02250859 - A Pharmacokinetic Study of Minocycline in Male and Female Volunteers Phase 1
Completed NCT01206348 - Combination Treatment for Moderate to Severe Acne Phase 4
Terminated NCT01193764 - Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris N/A
Completed NCT00725439 - An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne Phase 2
Completed NCT05640388 - Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects
Recruiting NCT05941065 - Study of Skin Balancing Gel Cream Safety and Influence of Skin Microbiome on Acne Prone Skin N/A
Recruiting NCT06120452 - A Clinical Trial to Evaluate the Effectiveness of an Acne Serum in Improving Facial Acne and Post-Acne Pigmentation N/A
Completed NCT04300010 - Blue Light Therapy of C. Acnes Phase 4
Recruiting NCT06202274 - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology N/A
Completed NCT04559022 - Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring N/A
Terminated NCT02431494 - Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris N/A
Completed NCT05469880 - Efficacy and Tolerance of Formula 609613 37 in Acneic Patients N/A
Completed NCT02944461 - Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Phase 4
Completed NCT01951417 - Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris Phase 4
Completed NCT01701024 - Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne Phase 3
Completed NCT01245946 - Photodynamic Therapy Compared to Adapalene 0.1% Gel Plus Doxycycline in the Treatment of Acne Vulgaris Phase 2